Skip to content
Screener

Schering-Plough SGP Common stock, par value (in dollars per share)

Common stock, par value (in dollars per share) at other companies

HRO
HarrowHROW
$00.0%
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
$00.0%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$00.0%
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Operating income-$15.4M-108%
Net income-$13.8M-56.6%
EPS (diluted)-$0.69+82.6%

Balance sheet

See full
Cash & equivalents$238.9M+312%
Total debt$1.6M
Total equity$250.1M+463%
Total assets$258.4M

Cash flow

See full
Operating cash flow-$13.5M-65.2%
CapEx$676.0K+312%
Free cash flow-$14.2M-70.0%

Valuation

See full
Market cap$841.55M+0.7%
Enterprise value$604.26M

Returns & leverage

See full
Return on equity-34.3%
Debt / equity
Current ratio38×

Where this comes from

Reported directly by Schering-Plough in its filing.

Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.

The source filing: Schering-Plough’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:30 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001778922-26-000035
Line itemAs of / March 31, 2026As of / December 31, 2025
Redeemable convertible preferred stock, $.00001 par value; 0 shares authorized, issued and outstanding as of March 31, 2026; 116,618,581 shares authorized, 20,341,968 shares issued and outstanding as of December 31, 2025 (aggregate liquidation preference of $0 and $200,878 as of March 31, 2026 and December 31, 2025, respectively)204,537
Stockholders' equity (deficit)
Preferred stock, $.00001 par value; 200,000,000 shares authorized, 0 shares issued and outstanding as of March 31, 2026; 0 shares authorized, issued, and outstanding as of December 31, 2025
Common stock, $.00001 par value; 1,000,000,000 shares authorized; 33,432,555 shares issued and outstanding as of March 31, 2026; 154,383,336 shares authorized; 2,203,620 shares issued and outstanding as of December 31, 2025
Common stock additional paid-in capital368,6605,893
Accumulated deficit(118,548)(104,730)
Total stockholders' equity (deficit)250,112(98,837)
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)$258,386$115,866

Item 1F. Financial Statements (Unaudited) Item 1. Financial Statements

FAQ

What is Schering-Plough's common stock, par value (in dollars per share)?
Schering-Plough (SGP) reported common stock, par value (in dollars per share) of $0.00 in Q1 2026.

Ask your AI about Schering-Plough's common stock, par value (in dollars per share).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude